ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc (ENTA)

4.90
-0.06
(-1.21%)
Closed February 07 4:00PM
4.90
0.00
( 0.00% )
Pre Market: 4:09AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
4.90
Bid
1.96
Ask
4.90
Volume
-
0.00 Day's Range 0.00
4.71 52 Week Range 17.80
Market Cap
Previous Close
4.90
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
551,033
Shares Outstanding
21,194,326
Dividend Yield
-
PE Ratio
-0.89
Earnings Per Share (EPS)
-5.48
Revenue
67.64M
Net Profit
-116.05M

About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of... Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Enanta Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ENTA. The last closing price for Enanta Pharmaceuticals was $4.90. Over the last year, Enanta Pharmaceuticals shares have traded in a share price range of $ 4.71 to $ 17.80.

Enanta Pharmaceuticals currently has 21,194,326 shares outstanding. The market capitalization of Enanta Pharmaceuticals is $103.85 million. Enanta Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.89.

ENTA Latest News

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R...

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2-3.921568627455.15.294.813652265.03484603CS
4-0.06-1.209677419354.965.75974.714276255.05151791CS
12-4.62-48.52941176479.529.694.715510336.37130234CS
26-7.64-60.925039872412.5413.434.713302917.7236463CS
52-7.48-60.420032310212.3817.84.7126306910.10391593CS
156-58.6-92.283464566963.579.4954.7125461325.66294244CS
260-50.83-91.207608110555.731024.7121988034.57403773CS

ENTA - Frequently Asked Questions (FAQ)

What is the current Enanta Pharmaceuticals share price?
The current share price of Enanta Pharmaceuticals is $ 4.90
How many Enanta Pharmaceuticals shares are in issue?
Enanta Pharmaceuticals has 21,194,326 shares in issue
What is the market cap of Enanta Pharmaceuticals?
The market capitalisation of Enanta Pharmaceuticals is USD 103.85M
What is the 1 year trading range for Enanta Pharmaceuticals share price?
Enanta Pharmaceuticals has traded in the range of $ 4.71 to $ 17.80 during the past year
What is the PE ratio of Enanta Pharmaceuticals?
The price to earnings ratio of Enanta Pharmaceuticals is -0.89
What is the cash to sales ratio of Enanta Pharmaceuticals?
The cash to sales ratio of Enanta Pharmaceuticals is 1.54
What is the reporting currency for Enanta Pharmaceuticals?
Enanta Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Enanta Pharmaceuticals?
The latest annual turnover of Enanta Pharmaceuticals is USD 67.64M
What is the latest annual profit for Enanta Pharmaceuticals?
The latest annual profit of Enanta Pharmaceuticals is USD -116.05M
What is the registered address of Enanta Pharmaceuticals?
The registered address for Enanta Pharmaceuticals is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Enanta Pharmaceuticals website address?
The website address for Enanta Pharmaceuticals is www.enanta.com
Which industry sector does Enanta Pharmaceuticals operate in?
Enanta Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BSBKBogota Financial Corporation
$ 12.60
(58.63%)
6
SPOKSpok Holdings Inc
$ 24.99
(53.97%)
5
STBXStarBox Group Holdings Ltd
$ 0.4944
(48.69%)
2.93M
MGOLMGO Global Inc
$ 0.5853
(41.04%)
14.81M
LENZLENZ Therapeutics Inc
$ 34.99
(38.41%)
1
PLRXPliant Therapeutics Inc
$ 3.41
(-56.23%)
44.63k
ANIKAnika Therapeutics Inc
$ 9.01
(-49.35%)
8
FXNCFirst National Corporation
$ 15.01
(-43.36%)
27
UNBUnion Bankshares Inc
$ 19.00
(-41.09%)
1
MYNAMynaric AG
$ 0.2505
(-34.82%)
16.47k
MGOLMGO Global Inc
$ 0.5853
(41.04%)
14.81M
CYNCYNGN Inc
$ 0.0775
(28.74%)
13.51M
NIVFNewGenIvf Group Ltd
$ 0.179
(33.58%)
3.49M
STBXStarBox Group Holdings Ltd
$ 0.4944
(48.69%)
2.93M
BHATBlue Hat Interactive Entertainment Technology
$ 0.0567
(5.00%)
1.03M

ENTA Discussion

View Posts
DewDiligence DewDiligence 10 hours ago
But how would “strategic alternatives” evaluation delay the quarter release, I mean unless something is bound to happen rather soon - like in next few days? Otherwise, they just need to add a mention to the release and should be good to go? There will not be any further delay—ENTA will almost certainly release the FY1Q15 financials via PR tomorrow because tomorrow is the SEC deadline for reporting. If ENTA is making a “strategic alternatives” announcement, that will be included in the FY1Q15 PR or in another PR issued concurrently.
👍️ 5
go seek go seek 11 hours ago
IMO there’s a good chance for positive news tomorrow.
👍️ 2
go seek go seek 1 day ago
You are extremely intelligent dewophile… thanks.
👍️ 3
dewophile dewophile 2 days ago
So either a leak or someone(s) was put off after the last release and lack of visibility to future earnings and/or lack of more concrete FY2025 guidance as DD pointed out.
I personally think part of the volume is traders hopping on board especially now that every share is 1/2 to 1/3 the price
👍️ 3
alertmeipp alertmeipp 2 days ago
This might get too far stretch but since we are all doing tea leaves ready - here is another one - the trading volume remains high since Nov 26, we have never seen a day with less than 300k volume since then.

We used to trade around 1/3 of that.
👍 1
dewophile dewophile 2 days ago
DD pointed out they didn’t mention when they would release next quarters earnings in the most recent earnings PR for the first time. So back on Nov 25 something might have been in the planning stages
👍️ 5
alertmeipp alertmeipp 2 days ago
Now looking back, I suspect the fire was on when 323 data came in even better than 938. They were talking about combo and different options even then.

And then they didn’t get a home run in ped studies for 938, that probably increased the urgency even more.

And then, as u said, on top, a competitor with same mechanism comes up with decent data.

I don’t mind a lower valuation buyout price if the deal comes quicker. There are lots of uncertainties in the market and Econ in general - so pile of cash won’t hurt.
👍️ 1
dewophile dewophile 2 days ago
see my last post it's a negative for ENTA to have a challenger with comparable top line data to 323, but we could also realize the benefits of some BD/strategic changes very soon
👍️ 2
dewophile dewophile 2 days ago
The problem is Shionogi didn't deliver much detail. but yeah if the top line was upper 70s to low 80s percent VL reduction vs PBO by PCR versus the nearly 89% (so more in line w 938 challenge data and a notch below 323 data than something on par with 323) then that would give ENTA more leverage. The dilemma now is does Shionogi have a 323 look alike, or is the top line as good but the rest of the data inferior (viral culture, speed of decline in culture, symptoms). As it stands it probably lights a fire under ENTA to do what they can to progress 323 with more haste, which as we have been saying probably translates to getting someone else to fund the trials, possibly at a detrimental cost in the long run. That is why a lowball partnership/sale may be on the table now versus holding out for HR data and a potentially more lucrative deal down the road. But it probably does move up timelines.
👍️ 3
alertmeipp alertmeipp 2 days ago
Don't forget the SHionogi data is very recent

Agree, good point, and the data is decent too, so be the first to the market could become a bigger factor on program's ultimate valuation.

Interesting time.
👍️0
Fred Kadiddlehopper Fred Kadiddlehopper 2 days ago
I think your point about the Shionogi data may be at the heart of the matter.
👍 3
dewophile dewophile 2 days ago
not sure how that would translate to later than usual quarter release

They have to decide how and when to prune the spend. Whether or not to stop clinical trials or see HR through. Don't forget the SHionogi data is very recent, so they may have wanted to see that data before finalizing a plan
👍 6 💯 1
dewophile dewophile 2 days ago
I agree w DD that this is a distinct possibility
You do make a point that usually if the company is ready to be sold they get interest ideally from multiple parties who then submit best and final and you don't go the "strategic alternatives" route.
So while you may not have that level of interest, the need to value the remaining royalty accurately requires some expertise, and you can shop the assets to a wider array of folks even in the VC world where ENTA may not have as many connections. They are well under cash, and there have been private companies in the immunology space that have had a good amount of interest from biotech VCs. So on top of the cash and whatever they can get for RSV, the immunology assets may have value to some of these folks.
So a strategic alternatives probably takes the best case scenario off the table - multiple bidders and a 500M+ value on the clinical assets, but it also probably gets you to 15+ based on cash, royalty, and any positive value for the assets including preclinical which again have garnered good interest including preclinical companies w identical assets
👍 7 😎 1
go seek go seek 2 days ago
Correction $6M
👍️0
go seek go seek 2 days ago
Jay Luly’s personal ENTA holding has dropped $60M in value since October. Motivation?
👍️0
alertmeipp alertmeipp 2 days ago
Actually nothing that unusual especially when the public failed miserably to value the company properly.

But not sure how that would translate to later than usual quarter release
👍️0
rwwine rwwine 2 days ago
"One possibility is that ENTA has hired an investment bank to evaluate “strategic alternatives” that enhance shareholder value—an action that would presumably be well received by the market."


Respectfully have a different opinion.  If this is the case (hiring an investment bank), I personally view that approach as a negative for ENTA.  That approach suggests the corporate executives have lost their way, specifically implying a lack of confidence in their approach going forward.  Just my simplistic point of view sir.  No disrespect.

👍️ 2
alertmeipp alertmeipp 2 days ago
But how would strategic alternatives evaluation delay the quarter release, I mean unless something is bound to happen rather soon - like in next few days? Otherwise, they just need to add a mention to the release and should be good to go?
👍 3
DewDiligence DewDiligence 2 days ago
One possibility is that ENTA has hired an investment bank to evaluate “strategic alternatives” that enhance shareholder value—an action that would presumably be well received by the market.

In any event, I’m not unduly concerned about the company’s radio silence. ENTA has plenty of inherent value that will be realized by shareholders one way or another.
👍️ 5
dewophile dewophile 2 days ago
Yes it is odd eom
👍️0
dewophile dewophile 2 days ago
Yes totally agree
👍️ 1
go seek go seek 2 days ago
If ENTA planned to release earnings Monday, wouldn’t we have an announcement of that today? To me the lack of transparency around earnings date is odd.
👍️0
alertmeipp alertmeipp 2 days ago
I agree that it’s negative in the sense that it introduced additional uncertainties on the balance sheet, especially when viewed alongside the strong 323 data. However, this is now a moot point since they plan to partner out the asset.

Overall, I don’t see the data as inherently negative. Given the trial size, both data sets have likely helped de-risk the RSV program, suggesting the asset’s value should rise rather than fall.

That said, they can’t sustain burning $100–150 million per year for another 2–3 years—otherwise, as jbog pointed out, they’ll be in serious trouble.

They allocated $160 million to R&D and $50 million to G&A. If RSV is no longer in the equation (assuming no upfront payments and no further clinical expenses), their costs should drop significantly—potentially to around $60 million for R&D and $30 million for G&A. This would reduce annual cash burn to under $25 million, significantly improving the company’s financial outlook.
👍️ 2
dewophile dewophile 3 days ago
The peds data was a negative for exactly the reasons we said going into it - enough efficacy to continue the program, but not enough that you have to devise a novel tool to try and tease out the efficacy signal (i.e. nothing concrete like shortened hospital stay). Then the patent was a negative. so if you start at 10 and you tack on two negatives, I guess you end up at 4.9. I think the current share price is totally insane, but you have smart posters like rocky and jbog that think enta is in dire straits (and that perhaps I am insane), so here we are
have a nice weekend
👍️ 8
alertmeipp alertmeipp 3 days ago
They had two calls for PED and challenge data and then attended the JPM in last few months - still the investment case is just not getting across.

RSV data got treated as negative I think mainly because they can’t seems to get partnership done for anything after myrovet
👍️0
dewophile dewophile 3 days ago
Lack of transparency is generally a bad thing, and your sentiment seems to be the prevailing one by investors. I already made a pitch for why this may be different so I'll leave it at that
This is continuing a bit of a trend though because they have been more opaque the last two quarters by not holding earnings calls. I think they are fed up w analysts and the stock price which is completely disconnected from the reality of the underlying business if you ask me
👍️ 2
alertmeipp alertmeipp 3 days ago
I am pretty certain that most of the other shareholders don’t even know about the “issue” we are discussing here.

No one other than us is paying attention to the fact that Enta is now looking to partner out its RSV.

How many know about the $32million tax refund? It is not much, but that alone is 1.5 bucks per share. 35 percent of the market cap ;)

Either we are sitting on a gold mine that is about to be discovered by the market or somehow we are all delusional here.

Not rare for biotech to trade below cash by a bit, especially when their lead program run into trouble.

But here, we are talking about 1/3 and a pipeline that is alive and well.

Odd and the selling continues
👍️ 1
alertmeipp alertmeipp 3 days ago
Management needs to do something more impactful to change the sentiment on this name

I think RSV partnership, followed by a significant expense will do it.

They will need to raise fund eventually, a depressed stock limit their options,
👍 3
alertmeipp alertmeipp 3 days ago
Bought some shares - this “delay” likely is a nothing burger but if something is really afoot, I agree that chance is good that it will be positive rather than negative.
👍 1
Jab44 Jab44 3 days ago
The mere fact shareholders are forced to prognosticate or predict something as simple as a quarterly announcement date is mind boggling. Mr Luly has been in the job for well over 20 years and if he can’t properly communicate to the people who pay his salary what else is he deficient in ?? Leaving shareholders in the dark without a quarterly meeting or some other means of communication when you seem to be floundering is not a recipe for success in my humble opinion.
👍 2
go seek go seek 3 days ago
Luly: It’s time to explore partnerships in EARNest! JPM call 1/15
👍️ 2
InefficientMarket InefficientMarket 3 days ago
Beginning with 2016, by this time they had issued a Q1 PR every year without fail. You have to back to 2015 to find Q1 Results issued `without a prior PR.
👍️ 3
dewophile dewophile 3 days ago
Schwab has earnings as tentative for Monday but they also had earnings for this week earlier in the week so until there is a company PR no one really knows
👍️ 1
Fred Kadiddlehopper Fred Kadiddlehopper 3 days ago
FWIW my brokerage account has earnings listed for Monday Feb 10th, after market close.
👍️0
biotech_researcher biotech_researcher 3 days ago
At least this is a low volume dump..
👍️0
InefficientMarket InefficientMarket 3 days ago
Perhaps they just didn't get the paperwork/accounting done on time this time around.

Put those odds at 1%. I went back through their history of last five years and this is first time they’re this late with a Q1 related PR. Something is afoot. Interesting, yet depressing at same time, that shorts feel comfortable holding under $5.
👍 3
dewophile dewophile 3 days ago
They have not been late reporting results ever, and as has been pointed out their accounting is super straight forward. I'm waiting to see if they release results today, which is exactly a year to the day from last Q1 earnings. If they don't, then I am a buyer/trader next week assuming change is coming, bc when you have >2x cash in the bank than the MC, change is generally a positive
👍 4
PioneerUniverse8 PioneerUniverse8 3 days ago
I think it is more of the same, Applying some generalization of Occam's razor principle here, i.e. that the simplest explanation is the most probable. Perhaps they just didn't get the paperwork/accounting done on time this time around.
👍 2
dewophile dewophile 3 days ago
That is the risk here, but wouldn't you think the weirdness in this earnings cycle means there are changes afoot and not just more of the same?
👍 2
PioneerUniverse8 PioneerUniverse8 3 days ago
Issues for shareholders emerge when the board prioritizes its own interests over those of the shareholders. I haven't seen this happen in ENTA yet, but there are plenty of example in biotech industry. The risk here is that board/CEO takes it easy with no sense of urgency and looks for partner rather passively, does not entertain the idea of selling the entire company (in pieces or as a whole), progresses with the pipeline and as a consequence burns through cash. So we may be stuck here for a while :)
👍 1
dewophile dewophile 3 days ago
They are not allowed to tell you when earnings is going to be, or if there is going to be a call along w it before it is public. My experience is that their IR is quite responsive
👍️ 1
dewophile dewophile 3 days ago
Bruce Carter is chairman of the board. He headed ZGEN through turbulent times and was able to salvage value for investors when BMY bought them out after their clinical drug bombed. I wouldn't be surprised if he pushes to offload all the clinical assets for whatever they can get, probably RSV has value but little else, and he gets the company more focused which frankly should get them to at least close to cash value minus restructuring costs/ finishing spend on RSV. They can probably generate 100M for their royalty interest and have a 30M refund due from the IRS, so doing the math, figuring an additional 50M to wind down RSV program etc., gets us to double digits pretty easily. Assuming they are 80+% enrolled in HR I would even unblind that trial early - it's pretty important to have that data to know the value of the RSV assets
👍️ 6
alertmeipp alertmeipp 3 days ago
Their IR is pretty useless for retail investors. You can try email or call them. Dont expect to get a response
👍️0
go seek go seek 3 days ago
Has anyone asked IR about earnings date?
👍️0
alertmeipp alertmeipp 3 days ago
They just gone thru their year-end process and their business model can’t be more straight forward with zero debt. They don’t even sell their own products and are not getting any other non royalty related income other than interest income. So chance of delay is because of accounting issue seems remote.

If they are indeed going to do a restructure and make the company officially focus on only immunology plus RSV (I assume they will incur cost for staff cut and asset write off etc). I wish they just auction off all the other virology assets include 235 and all related IP. Get whatever they can and move on.

Now looking back, maybe that’s why they removed hpv and 235 partnership from their business goals in latest update.
👍️ 1
dewophile dewophile 3 days ago
Delaying earnings can be bad too but in this case there is far more potential for a positive catalyst even if there is no deal making. They already intimated they are looking to partner RSV so they can formalize that which means no further clinical development in antivirals after the adult HR study. That would mean a restructuring to a preclinical company effectively which given the cash position should be very good for the stock price.
👍️ 5
alertmeipp alertmeipp 3 days ago
Interesting observation. However, unless they are very close to finalizing the deal, it's hard to see why they would delay the quarterly release and earnings call for it.

They could simply release the earnings first and schedule a separate call once the partnership is officially announced.

I suppose we'll find out in the coming days. Hoping for a nice suprise here.
👍️0
alertmeipp alertmeipp 4 days ago
Re: THRD: Moved up sharply today. Still near all time low. Interesting name but I don’t have enough energy to follow another name in such a distressing sector. Hope it continues to go up and bring more interest towards this kit/stat area
👍️0
DC15 DC15 4 days ago
Relict news: Program of 2023, has since been dropped, presumably.
👍️0
alertmeipp alertmeipp 4 days ago
Imagine the market reaction if they manage to cut a nice RSV deal, will be extraordinary;)
👍️ 3

Your Recent History

Delayed Upgrade Clock